2020
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS
Riess JW, Jahchan NS, Das M, Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment And Research Communications 2020, 23: 100174. PMID: 32413603, PMCID: PMC7572629, DOI: 10.1016/j.ctarc.2020.100174.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerMetastatic small cell lung cancerRadiographic progression-free survivalHigh-grade neuroendocrine carcinomaMedian overall survivalProgression-free survivalTricyclic antidepressantsClinical trialsLung cancerPrior chemotherapyFree survivalStable doseOverall survivalRadiographic benefitStudy entryNeuroendocrine carcinomaPreclinical modelsAntitumor effectsGrade 1Phase IIa clinical trialDose-escalation clinical trialHigh-grade neuroendocrine tumorsNeurocognitive adverse eventsEscalation clinical trial
2016
Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors
Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors. Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/mpa.0000000000000659.Peer-Reviewed Original ResearchConceptsRadiographic response rateAdvanced neuroendocrine tumorsPrimary end pointProgression-free survivalNeuroendocrine tumorsPancreatic neuroendocrine tumorsNeuroendocrine carcinomaProspective phase II studyB studyEnd pointProlonged disease stabilityPhase II studyEffectiveness of bevacizumabDifferentiated neuroendocrine carcinomaPredictable toxicityRR-18Maintenance therapyDisease stabilityII studyRadiographic responsePatientsResponse rateNET subtypesBevacizumabMonths